Menu
Recruiting NCT02038660

Drug-Eluting Balloon Registry in Routine Clinical Practice

Observational Coronary Artery Disease Angioplasty, Balloon

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Balloon angioplasty.
Who it may be relevant to
Registry conditions: Coronary Artery Disease, Angioplasty, Balloon. Basic parameters: from 20 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Evaluation of Effectiveness and Safety of Drug-Eluting Balloon in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study

Overview

The purpose of this study is to evaluate long-term effectiveness and safety of patients with coronary disease treated with drug eluting balloon in real world practice.

Interventions

  • Device Balloon angioplasty

Primary outcome measures

  • Composite Event [Time frame: 1year]
Secondary outcome measures (10)
  • All cause death [Time frame: 5year]
  • Cardiac death [Time frame: 5year]
  • Myocardial infarction [Time frame: 5year]
  • Composite event [Time frame: 5year]
  • Composite event [Time frame: 5year]
  • Target vessel revascularization [Time frame: 5year]
  • Target lesion revascularization [Time frame: 5year]
  • Stent thrombosis [Time frame: 5year]
  • Stroke [Time frame: 5year]
  • Procedural Success [Time frame: 3day]

Eligibility criteria

Inclusion criteria

  • After pre dilatation residual stenosis 30% and less and also without vessel dissection interrupted blood flow
  • Age 20 and more
  • Treated with Balloon angioplasty
  • Signed informed consent and agreed to follow protocol

Exclusion criteria

  • Allergy to paclitaxel, antiplatelet
  • History of side effect to heparin, aspirin, thienopyridines
  • History of bleeding tendency, coagulation disorder, blood transfusion reaction

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

South Korea · 9 centers
  • Soon Chun Hyang University Hospital Bucheon — Bucheon-si
  • Keimyung University Dongsan Medical Center — Daegu
  • The Catholic University of Korea, Daejeon ST. Mary's Hospital — Daejeon
  • Chonnam National University Hospital — Gwangju
  • Dong-A Medical Center — Pusan
  • Asan Medical Center — Seoul
  • Gangnam Severance Hospital — Seoul
  • Korea University Guro Hospital — Seoul
  • … and 1 more center

Identifiers

NCT: NCT02038660 · AMCCV2013-10

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗